Connect to MCP

Claude DesktopClaude Code (CLI)ChatGPTCursorVS Code

Femasys Valuation Multiples

Discover revenue and EBITDA valuation multiples for Femasys.

Start Free TrialSee companies similar to Femasys

Femasys Overview

About Femasys

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Founded

2004

HQ

United States

Employees

71

Financials (LTM)

Revenue: $3M
Net Income: ($17M)

EV

$23M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Femasys Financials

Femasys reported last 12-month revenue of $3M.

In the same LTM period, Femasys generated $2M in gross profit and had net loss of ($17M).

Femasys P&L

In the most recent fiscal year, Femasys reported revenue of $2M and EBITDA of ($16M).

Femasys is unprofitable as of last fiscal year, with gross margin of 62%, EBITDA margin of (697%), and net margin of (812%).

See analyst estimates for Femasys
LTMLast FY202320242025202620272028
Revenue$3M$2M$1M$2M$2M
Gross Profit$2M$1M$692K$1M$1M
Gross Margin70%62%65%67%62%
EBITDA-($16M)($13M)($16M)($16M)
EBITDA Margin-(697%)(1229%)(1002%)(697%)
EBIT Margin(572%)(767%)(1353%)(1092%)(767%)
Net Profit($17M)($19M)($14M)($19M)($19M)
Net Margin(532%)(812%)(1329%)(1155%)(812%)
Net Debt-($6M)---

Financial data powered by Morningstar, Inc.

Femasys Stock Performance

Femasys has current market cap of $19M, and enterprise value of $23M.

Femasys' stock price is $2.29.

Femasys has an EPS (earnings per share) of $-2.22.

See more trading valuation data for Femasys
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$23M$19M166.0%---$-2.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Femasys Valuation Multiples

Femasys trades at 7.0x EV/Revenue multiple, and (1.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Femasys

Femasys Financial Valuation Multiples

As of August 17, 2026, Femasys has market cap of $19M and EV of $23M.

Femasys has a P/E ratio of (1.1x).

LTMLast FY202320242025202620272028
EV/Revenue7.0x9.8x21.0x13.8x9.8x
EV/EBITDA-(1.4x)(1.7x)(1.4x)(1.4x)
EV/EBIT(1.2x)(1.3x)(1.6x)(1.3x)(1.3x)
EV/Gross Profit10.1x15.9x32.6x20.8x15.9x
P/E(1.1x)(1.0x)(1.3x)(1.0x)(1.0x)
EV/FCF-(1.2x)(2.0x)(1.1x)(1.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Femasys Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Femasys Margins & Growth Rates

Femasys grew revenue by 64% but net profit decreased by 13% in the last fiscal year.

In the most recent fiscal year, Femasys reported gross margin of 62%, EBITDA margin of (697%), and net margin of (812%).

See estimated margins and future growth rates for Femasys

Femasys Margins

Last FY202420252026202720282029
Gross Margin62%67%62%72%
EBITDA Margin(697%)(1002%)(697%)-
EBIT Margin(767%)(1092%)(767%)(502%)
Net Margin(812%)(1155%)(812%)(431%)
FCF Margin(842%)(1246%)(842%)-

Femasys Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth64%52%41%64%
Gross Profit Growth92%57%31%92%
EBITDA Growth-24%(2%)-
EBIT Growth7%23%(1%)7%
Net Profit Growth(13%)32%(1%)(13%)
FCF Growth-78%(5%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Femasys Operational KPIs

Femasys' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Femasys
LTMLast FY202320242025202620272028
Revenue per Employee-$0.0M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue184%194%61%247%194%
G&A Expenses to Revenue220%290%640%388%290%
R&D Expenses to Revenue227%330%672%504%330%
Opex to Revenue-829%1418%1158%829%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

Femasys Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all Femasys competitors and their valuation data.

Start Free Trial

Femasys VC Funding History

Before going public, Femasys raised $58M in total equity funding, across 5 rounds.

Femasys Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-17Series C-$4M-Femasys raised $4.0M in an undisclosed round on January 19, 2017, led by Salem Partners. This followed prior rounds including $40.0M in December 2016 also from Salem Partners, $3.3M in August 2016, and $10.2M Series B in April 2015 from Legacy Capital Partners. The company develops in-office therapeutic and diagnostic products for women's health, including fertility and permanent birth control solutions. Femasys focuses on biomedical innovations with products like FemaSeed for intratubal insemination and FemVue for fallopian tube assessment, holding FDA clearance and international approvals. The firm has pursued commercialization in the U.S., Canada, Europe, and Japan.
Dec-16Series C-$40M-Femasys Inc. closed a $40 million Series C financing round on December 15, 2016, arranged and led by Los Angeles-based investment bank Salem Partners, with multiple institutional investors, family offices, and a multibillion-dollar global medical device company participating. The company is a developer of innovative medical devices for women's healthcare, with FemBloc as its flagship product—a non-surgical permanent contraception solution designed to be performed in a physician's office that occludes the fallopian tubes. The Series C funding was earmarked primarily to support pivotal testing of FemBloc, with the goal of generating clinical data to support a planned premarket approval application with the FDA. The company had received an Investigational Device Exemption from the FDA to conduct its first clinical trial for the complete FemBloc system, with the study set to begin in early 2017. FemBloc was positioned to fill an unmet need for a safe, permanent contraceptive method that does not require specialized surgical skills or expensive surgical equipment, differentiating it from existing female sterilization options such as tubal ligation or hysteroscopic procedures.
Aug-16Series C-$3M-Femasys Inc., a developer of innovative medical devices for women's healthcare, closed a $40 million Series C financing round on December 15, 2016. The oversubscribed round was arranged by Salem Partners, which also participated as a principal investor, alongside multiple institutional investors, family offices, and a multibillion-dollar global medical device company. The funding supports the pivotal clinical trial for FemBloc, a non-surgical permanent contraception solution designed for in-office procedures to occlude fallopian tubes. Femasys received FDA investigational device exemption approval for the FemBloc trial, set to start early 2017, advancing toward premarket approval. FemBloc addresses unmet needs by avoiding surgery, anesthesia, and specialized equipment required for existing female sterilization options.
Apr-15Series BMario Family Funds; Salem Partners; Legacy Capital Partners$10M-Femasys Inc., a developer of innovative medical devices for the women's healthcare market, completed a $10.2 million Series B financing round on April 29, 2015. The round was led by Legacy Capital Partners and included Mario Family Partners and Salem Partners. Funds were allocated to achieve the Investigational Device Exemption milestone for FemBloc, a non-surgical female sterilization device using a biomaterial delivered via catheter, and to expand global commercialization of diagnostic products for female infertility and cervical cancer. John Adams Jr., founder of Legacy Capital Partners and former CEO of Adams Respiratory Therapeutics, joined the Femasys board. The investor syndicate highlighted Femasys' potential to address gaps in women's healthcare with innovative technologies. Femasys focused on minimally invasive solutions to reduce risks compared to surgical sterilization.
Sep-13Pre-seed-$200K--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Femasys

When was Femasys founded?Femasys was founded in 2004.
Where is Femasys headquartered?Femasys is headquartered in United States.
How many employees does Femasys have?As of today, Femasys has over 71 employees.
Is Femasys publicly listed?Yes, Femasys is a public company listed on Nasdaq.
What is the stock symbol of Femasys?Femasys trades under FEMY ticker.
When did Femasys go public?Femasys went public in 2021.
Who are competitors of Femasys?Femasys main competitors include
What is the current market cap of Femasys?Femasys' current market cap is $19M.
What is the current revenue of Femasys?Femasys' last 12 months revenue is $3M.
What is the current revenue growth of Femasys?Femasys revenue growth (NTM/LTM) is 139%.
What is the current EV/Revenue multiple of Femasys?Current revenue multiple of Femasys is 7.0x.
Is Femasys profitable?No, Femasys is not profitable.
What is the current net income of Femasys?Femasys' last 12 months net income is ($17M).
How many companies Femasys has acquired to date?Femasys hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Femasys has invested to date?Femasys hasn't invested in any companies yet (or none have been disclosed publicly).

Lists including Femasys

Largest Companies in the US

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial